MedTrace Logo

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

NCT01980472 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-02-27

No results posted yet for this study

Summary

A phase II Study of an adapted chemotherapy regimen plus bevacizumab in elderly non-small cell lung cancer patients selected by geriatric assessment

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

BIOLOGICAL

bevacizumab, carboplatin and paclitaxel

4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity

Sponsors & Collaborators

  • Grupo de Investigación y Divulgación Oncológica

    lead OTHER

Principal Investigators

  • Oscar Juan Vidal, Dr. · Grup d'investigació i divulgació en oncologia

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-06-30
Completion
2017-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01980472 on ClinicalTrials.gov